



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/051,776	01/16/2002	Edward Pierson	100507-1	1512
22466	7590	07/09/2003		
ASTRA ZENECA PHARMACEUTICALS LP GLOBAL INTELLECTUAL PROPERTY 1800 CONCORD PIKE WILMINGTON, DE 19850-5437			EXAMINER PATEL, SUDHAKER B	
			ART UNIT 1624	PAPER NUMBER 10
			DATE MAILED: 07/09/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	Application No.	Applicant(s)
	10/051,776	PIERSON ET AL.
	Examiner	Art Unit
	Sudhaker B. Patel, D.Sc.Tech.	1624

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 22 August 2002.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-9 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-9 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) The proposed drawing correction filed on \_\_\_\_\_ is: a) approved b) disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) The oath or declaration is objected to by the Examiner.

#### Priority under 35 U.S.C. §§ 119 and 120

- 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
  2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) The translation of the foreign language provisional application has been received.
- 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

#### Attachment(s)

- 1) Notice of References Cited (PTO-892)
- 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_\_.

- 4) Interview Summary (PTO-413) Paper No(s). 10.
- 5) Notice of Informal Patent Application (PTO-152)
- 6) Other: \_\_\_\_\_

**DETAILED ACTION**

***Election/Restrictions***

1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims (in part) 1-9, drawn to compounds, compositions for generic Formula (I) wherein X = Oxygen; R2 = open chain/bridge i.e. Formula ii, classified in class 549, subclasses various depending on the nature of variables R1,R5-R7, Y.
  - II. Claims(in part) 1, drawn to compounds, compositions for generic Formula (I) wherein X = Sulfur, R2 = open chain/bridge i.e. Formula ii classified in class 549, subclasses various depending on the nature of variables R1,R5-R7, Y.
  - III. Claims(in part)1, drawn to compounds, compositions for generic Formula (I) wherein X = NH/N, R2 = open chain/bridge i.e. Formula ii classified in class 548, subclasses various depending on the nature of variables R1,R5-R7, Y.
  - IV. Claims(in part)1, drawn to compounds, compositions of generic Formula (I) wherein R2 = Formula wherein the ring has 2 N, n = 3,4, classified in class 540, subclasses various depending on the nature of variables

R1,R5-R7, Y. Further restriction/election will be required as there are many unknowns.

- V. Claims(in part) 1, drawn to R2 = Formula iii or iv, wherein P = heterocycle, classified in various classes, subclasses various depending on the nature of variables R1,R5-R7, Y. Further restriction/election will be required as there are many unknowns.
- VI. Claims(in part) 1, drawn to compounds, compositions not included in above Groups I-V.

The inventions are distinct, each from the other because of the following reasons:

The compounds of Groups I-III are drawn to:

- (1). Structurally diverse compounds with different cores that are made and used independently of each other;
- (2). Compounds are separately classified;
- (3) Classes will require separate literature searches;
- (4) Compounds are not art recognized equivalents, and additionally,
- (5). The groups lack unity of invention(see MPEP 803.02).

The only common technical feature, which is present among the groups .is presence of a benzene ring with R1, R2which is not patentably distinct.

Based on above stated data i.e: (1) - (5),, claim 1 also lacks unity of invention.

2. Inventions I-VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case compounds of Gaster et al(J. Med. Chem., 41,1218-35(1998) can also be used for the utility as claimed herein.

Art Unit: 1624

3. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Groups II-VI, restriction for examination purposes as indicated is proper.

4. Claim 1 is generic to a plurality of disclosed patentably distinct species comprising -Chromene-morpholine/thiomorpholine/piperazine falling in class 544; -Chromene-imidazole/thiadiazole. Falling in class 548; -Chromene-diazepan falling in class 540; -When X = N/NH, falling in class 546; -When X = S falling in class 549.

These compounds with variable R2 having different meanings will further generate many species.

4. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species with all variable exactly and definitely defined in the working example(s), even though this requirement is traversed.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Art Unit: 1624

5. A telephone call was made to Mr. G. Gilbert on 7/7/03 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sudhaker B. Patel, D.Sc.Tech. whose telephone number is 703 308 4709. The examiner can normally be reached on 6:30 to 5:00 pm; Monday-Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Mukund J. Shah can be reached on 703 308 4716 or Sr. Examiner Mr. Richard Raymond at 703 308 4523. The fax phone numbers for the organization where this application or proceeding is assigned are 703 308 4556 for regular communications and 703 308 4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308 1235.

SP/-  
July 7, 2003

Mukund J. Shah  
MUKUND J. SHAH  
SUPERVISORY PATENT EXAMINER  
GROUP 1600